Mounting evidence reveal that CHIP can inhibit tumor proliferation, invasion, and progression in several malignancies, by regulating the ubiquitination and proteasomal degradation of a variety of oncogenic proteins, including TNF receptor-associated factor 2 (TRAF2) [23], nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) [24], SRC-3 [25], receptor tyrosine-protein kinase erbB-2 (cErbB2/Neu) [26, 27], epidermal growth factor receptor (EGFR) [28], protein arginine methyltransferase 5 (PRMT5) [29], c-myc [30], and c-Met [31] and so on. Here, PRMT5 is linked to neoplasm.